A new study published in Agricultural Sciences reveals genetic engineering of soy disrupts the plant’s natural ability to control stress, and invalidates the FDA’s current regulatory framework of “substantial equivalence” used for approval of GMOs.
The study, led by Dr. V.A. Shiva Ayyadurai, an MIT-trained systems biologist, utilizes his latest invention, CytoSolve, a 21st century systems biology method to integrate 6,497 in vitro and in vivo laboratory experiments, from 184 scientific institutions, across 23 countries, to discover the accumulation of formaldehyde, a known carcinogen, and a dramatic depletion of glutathione, an anti-oxidant necessary for cellular detoxification, in GMO soy, indicating that formaldehyde and glutathione are likely critical criteria for distinguishing the GMO soy from non-GMO soy.
The study concludes the U.S. government’s current standards for safety assessment of GMOs, based on the principle of “substantial equivalence,” is outdated and unscientific for genetically engineered food since it was originally developed for assessing the safety of medical devices in the 1970s.
Dr. Ayyadurai said, “This is not a pro- or anti-GMO question. But, are we following the scientific method to ensure the safety of our food supply? Right now, the answer is ‘no’. We need to, and we can, if we engage in open, transparent, and collaborative scientific discourse, based on a systems biology approach.”
“The results demand immediate testing along with rigorous scientific standards to assure such testing is objective and replicable. It’s unbelievable such standards for testing do not already exist. The safety of our food supply demands that science deliver such modern scientific standards for approval of GMOs.”
A concluding peer review statement noted that due to Dr. Ayyadurai’s study: “We believe it premature to approve GMOs and to consider them safe.”